Purpose built
The Haystack MRD difference
MRD testing demands high-sensitivity ctDNA detection. Haystack MRD is a tumor-informed, next-generation MRD test that detects ultralow levels of ctDNA to uncover residual disease after definitive surgery.
A track record of Innovation and leadership
Haystack MRD is the product of more than 20 years of pioneering work in liquid biopsy technologies and is purpose-built for ultrasensitive ctDNA detection.
Haystack MRD has been developed on the foundational work of cancer genomics pioneers, whose discoveries have transformed clinical practice for cancer patients.
Guide treatment with Confident MRD results
Haystack MRD’s technology enables ultrasensitive ctDNA testing with the ability to detect 95% of cases at 0.0006% tumor fraction. With an exceptionally low limit of detection, you can uncover the insights you need to help make confident treatment decisions.
-
Exceptional sensitivity
-
Tumor informed
-
Personalized
Prioritized patient access with The power of Quest
End-to-end reliability powered by Quest Diagnostics credentialed staff, labs, logistics, service, reporting, test menu, and technology. Haystack MRD is seamlessly integrated into Quest Diagnostics advanced oncology testing for easy access and reliability.
Purpose built
The Haystack MRD difference
MRD testing demands high-sensitivity ctDNA detection. Haystack MRD is a tumor-informed, next-generation MRD test that detects ultralow levels of ctDNA to uncover residual disease after definitive surgery.
- Innovation and leadership
-
A track record of Innovation and leadership
Haystack MRD is the product of more than 20 years of pioneering work in liquid biopsy technologies and is purpose-built for ultrasensitive ctDNA detection.Haystack MRD has been developed on the foundational work of cancer genomics pioneers, whose discoveries have transformed clinical practice for cancer patients. - Confident MRD results
-
Confident MRD results
Haystack MRD’s technology enables ultrasensitive ctDNA testing with the ability to detect 95% of cases at 0.0006% tumor fraction. With an exceptionally low limit of detection, you can uncover the insights you need to help make confident treatment decisions.-
Exceptional sensitivity
-
Tumor informed
-
Personalized
-
Track 50 variants
-
- The power of Quest
A track record of Innovation and leadership
Haystack MRD is the product of more than 20 years of pioneering work in liquid biopsy technologies and is purpose-built for ultrasensitive ctDNA detection.
Haystack MRD has been developed on the foundational work of cancer genomics pioneers, whose discoveries have transformed clinical practice for cancer patients.
Confident MRD results
Haystack MRD’s technology enables ultrasensitive ctDNA testing with the ability to detect 95% of cases at 0.0006% tumor fraction. With an exceptionally low limit of detection, you can uncover the insights you need to help make confident treatment decisions.
-
Exceptional sensitivity
-
Tumor informed
-
Personalized
-
Track 50 variants
Industry upates
Recent news
Find out what’s happening at Haystack Oncology and stay up-to-date with industry news.
Learn about Haystack MRD™ at ASCO 2025
Haystack MRD™ is proud to be part of the American Society of Clinical Oncology (ASCO) Annual Meeting, where oncology innovation takes center stage. Join us at booth #11069 to explore how our ctDNA-based assay delivers confidence in detecting even the smallest traces of residual disease.
Haystack MRD™ by Quest Diagnostics® at SSO 2025
We invite you to connect with us at SSO 2025 to learn how Haystack MRD can help guide treatment decisions with confidence. From the perioperative setting to recurrence surveillance, Haystack MRD tracks ctDNA across the treatment management journey—empowering oncologists to make informed, timely treatment decisions.
Two leading oncologists take a deep dive into how groundbreaking advancements are providing a clearer crystal ball for guiding patient care
Oncologists like Dr Doug Flora and Dr Debra Patt are realists. But when they began to use new tools to find cancer that surgery or treatment might have missed, something exciting happened.
